Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat PK and DDI Study in Advanced Malignancies
NCT04537715Phase 1Completed
- Sponsor
- Epizyme, Inc.
- Start
- Apr 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of tazemetostat in malignant neoplasms (advanced stage), solid tumor and hematologic malignancy (2 arms), sponsored by Epizyme, Inc. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to 12 Hours and Maximum Observed Plasma Concentration. Started Apr 2020; status: completed.
02
Drugs
tazemetostat
03
Conditions
malignant neoplasms (advanced stage)solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT04537715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537715.